The potential value of diagnostic and predictive serum biomarkers for preeclampsia

• Published in: Romanian journal of morphology and embryology Vol. 62; no. 4; pp. 981 - 989
• Main Authors: Dijmărescu, Anda Lorena, Boldeanu, Lidia, Radu, Mirela, Rotaru, Ionela, Siminel, Mirela Anişoara, Manolea, Maria Magdalena, Vrabie, Sidonia Cătălina, Novac, Marius Bogdan, Boldeanu, Mihail Virgil, Tănase, Florentina
• Format: Journal Article
• Language: English
• Published: Romania Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest 01.10.2021
• Subjects: Biomarkers; Case-Control Studies; Chemokine CXCL10; Female; Humans; Hypertension; Matrix Metalloproteinase 13; Original Paper; Pre-Eclampsia - diagnosis; Pregnancy; Prospective Studies; Vascular Endothelial Growth Factor A
• ISSN: 1220-0522; 2066-8279
• DOI: 10.47162/RJME.62.4.10

Preeclampsia (PE), one of the classes of hypertensive pregnancy disorders, is one of the three causes of maternal morbidity and mortality worldwide. The angiogenic and anti-angiogenic factors are useful markers in predicting and diagnosing PE. This study aims to detect and measure the serum level of some biomarkers [hypoxia-inducible factor-1 subunit alpha (HIF-1A), vascular endothelial growth factor (VEGF), interferon-gamma-inducible protein of 10 kDa (IP-10), matrix metalloproteinase-13 (MMP-13)] in patients with PE and their correlation with the severity of the disease, to find a good predictor for PE. This prospective study aims to monitor 48 pregnant women who address obstetric consultation and who present risk factors for PE, and a control group with characteristics similar to the study group. Patients were divided into three groups: Group I (n=15) including normal pregnant (NP) women with blood pressure <140∕90 mmHg, without proteinuria, Group II (n=18) including patients with mild PE (MildPE), Group III (n=15) including patients with severe PE (SeverePE). The analysis of serum biomarkers was based on a quantitative sandwich enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's instructions. In our study, we found that all biomarkers investigated have higher concentrations in the serum of patients with SeverePE and MildPE than those in the control subjects (Group I, NP), the concentrations were increasing along with the disease activity. The means concentrations of HIF-1A, VEGF, IP-10, MMP-13, better correlated with indices in SeverePE group than in MildPE group. We found that VEGF was the biomarker that best correlates with indices that assess the severity of PE. The best separation of patients with SeverePE from those with MildPE can be done with the help of MMP-13 (82% accuracy), followed by VEGF (80.40% accuracy) and the least good detection being done by dosing IP-10. We can say that, due to high specificity diagnostic accuracy, determination of serum concentrations of MMP-13 and VEGF, could be useful in the diagnosis and distinguishing of patients with SeverePE and may prove useful in the monitoring of the disease course.